National Institutes of Health Awards Second Research Grant to Nanovis
Nanovis’ Deeply Porous Spinal Implants with Nanotube-Enhanced Surfaces May Significantly Improve Patient Recovery from Spinal Fusion Procedures
Carmel, Ind. (March 8, 2016) – Nanovis, a life sciences company committed to developing scientifically advanced regenerative platforms for implantable medical devices, today announced a grant award from the National Institute on Aging, part of the National Institutes of Health (NIH). To date, Nanovis’ spinal nanotechnology platform and soft tissue regeneration nanotechnology platform have received eight competitive, peer reviewed grants from the NIH and other research organizations.
The grant will be used to fund pre-clinical studies exploring the potential benefits of Nanovis’ deeply porous FortiCore® interbody fusion devices enhanced with Nanovis’ nanotube technology. The FortiCore®® interbody fusion device will be studied together with Nanovis’ nanosurfaced FortiFix® pedicle screws to determine their potential impact on improving aspects of recovery following spinal fusion procedures. Nanovis’ nanotube technology and nanosurfaced pedicle screws are currently in pre-clinical development.
This research is being led by Dr. Rick Guyer, co-founder of the Texas Back Institute and Director of the Spine Fellowship Program, and Dr. Jean-Jacques Abitbol, Past-President NASS, Founder California Spine Group. Dr. Abitbol and Dr. Guyer are also leading other Nanovis research efforts funded by the NIH studying the benefits of nanotube enhanced FortiCore®® spinal implants. (Additional details about the study and grant are available in the September 22, 2015 press release: “National Institutes of Health Awards Research Grant…”)
“The surface structure of medical devices plays a critical role in how the body heals around an implant. Mimicking natural surfaces at the nano scale, about the size of a protein, to encourage natural regenerative processes may improve results for patients challenged to quickly heal on their own,” said Dr. Rick, Guyer, co-investigator of the study. “Nanovis’ science-focused approach to developing unique implant technologies shows significant potential to enhance performance. This research will evaluate the differentiated capabilities and unique potential of these advanced technologies.”
“Gaining the attention and support of the NIH for Nanovis’ technology platforms and research is gratifying,” said Matt Hedrick, CEO, Nanovis. “Our deeply porous FortiCore®® interbody fusion device are increasingly being adopted by leading surgeons and hospital networks driving accelerated company growth. As we progress forward, we continue to invest in the fundamental science at the core of our uniquely differentiated technologies. Grants from the NIH help us continue to discover potential applications to improve the future of healthcare.”
Nanovis’ mission is to lead our select markets with science-enhanced, life-improving technologies. The Company’s patented and proprietary regenerative technology platforms provide differentiated surface advantages enabling the potential for existing medical devices to achieve new outcomes. Focused on aggressive, sustainable growth across multiple markets, Nanovis is commercializing science-driven platforms: the deeply porous scaffold currently available with the FortiCore® line of interbody fusion devices; a developmental nanosurface technology; and developmental surface technology with anti-colonization and anti-microbial capabilities in pre-clinical studies.
For more information about Nanovis, FortiCore®, FortiFix or other proprietary Nanovis science-enhanced technologies,
please visit www.nanovisinc.com or call 1-877-907-NANO.
Media Contact: Levitate Stacey Holifield or Rachel Batdorff (617) 233-3873 email@example.com / firstname.lastname@example.org